Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
Management of Graves’ orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab su...
| 發表在: | Türk Oftalmoloji Dergisi |
|---|---|
| Main Authors: | , , , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
Turkish Ophthalmology Society
2017-01-01
|
| 主題: | |
| 在線閱讀: | http://www.oftalmoloji.org/article_14247/Rituximab-Treatment-In-A-Patient-With-Active-Graves-Orbitopathy-And-Psoriasis |